252 related articles for article (PubMed ID: 25604133)
1. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
Moses MA; Henry EC; Ricke WA; Gasiewicz TA
Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
[TBL] [Abstract][Full Text] [Related]
2. (-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2.
Li Y; Zhang T; Jiang Y; Lee HF; Schwartz SJ; Sun D
Mol Pharm; 2009; 6(4):1152-9. PubMed ID: 19438225
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo.
Tran PL; Kim SA; Choi HS; Yoon JH; Ahn SG
BMC Cancer; 2010 Jun; 10():276. PubMed ID: 20537126
[TBL] [Abstract][Full Text] [Related]
4. (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor.
Yin Z; Henry EC; Gasiewicz TA
Biochemistry; 2009 Jan; 48(2):336-45. PubMed ID: 19113837
[TBL] [Abstract][Full Text] [Related]
5. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
6. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
7. Biological and Mechanistic Characterization of Novel Prodrugs of Green Tea Polyphenol Epigallocatechin Gallate Analogs in Human Leiomyoma Cell Lines.
Ahmed RS; Liu G; Renzetti A; Farshi P; Yang H; Soave C; Saed G; El-Ghoneimy AA; El-Banna HA; Foldes R; Chan TH; Dou QP
J Cell Biochem; 2016 Oct; 117(10):2357-69. PubMed ID: 26950525
[TBL] [Abstract][Full Text] [Related]
8. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor.
Khandelwal A; Hall JA; Blagg BS
J Org Chem; 2013 Aug; 78(16):7859-84. PubMed ID: 23834230
[TBL] [Abstract][Full Text] [Related]
10. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
11. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells.
Karkoulis PK; Stravopodis DJ; Margaritis LH; Voutsinas GE
BMC Cancer; 2010 Sep; 10():481. PubMed ID: 20828379
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
Eskew JD; Sadikot T; Morales P; Duren A; Dunwiddie I; Swink M; Zhang X; Hembruff S; Donnelly A; Rajewski RA; Blagg BS; Manjarrez JR; Matts RL; Holzbeierlein JM; Vielhauer GA
BMC Cancer; 2011 Oct; 11():468. PubMed ID: 22039910
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells.
Matthews SB; Vielhauer GA; Manthe CA; Chaguturu VK; Szabla K; Matts RL; Donnelly AC; Blagg BS; Holzbeierlein JM
Prostate; 2010 Jan; 70(1):27-36. PubMed ID: 19739131
[TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein.
Palermo CM; Westlake CA; Gasiewicz TA
Biochemistry; 2005 Apr; 44(13):5041-52. PubMed ID: 15794642
[TBL] [Abstract][Full Text] [Related]
15. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
Kang BH; Siegelin MD; Plescia J; Raskett CM; Garlick DS; Dohi T; Lian JB; Stein GS; Languino LR; Altieri DC
Clin Cancer Res; 2010 Oct; 16(19):4779-88. PubMed ID: 20876793
[TBL] [Abstract][Full Text] [Related]
16. (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity.
Kim SO; Kim MR
Int J Oncol; 2013 Jan; 42(1):349-58. PubMed ID: 23135610
[TBL] [Abstract][Full Text] [Related]
17. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.
Thangapazham RL; Singh AK; Sharma A; Warren J; Gaddipati JP; Maheshwari RK
Cancer Lett; 2007 Jan; 245(1-2):232-41. PubMed ID: 16519995
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
19. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo.
Lee SC; Chan WK; Lee TW; Lam WH; Wang X; Chan TH; Wong YC
Nutr Cancer; 2008; 60(4):483-91. PubMed ID: 18584482
[TBL] [Abstract][Full Text] [Related]
20. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]